Peptide Library

Human study PLS-00067

Mitochondrial dysfunction is associated with cognitive impairment in adults with OSA without dementia.

Cross-sectional study · 268 participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Mitochondrial dysfunction is associated with cognitive impairment in adults with OSA without dementia.primary · Sleep medicine · 2024-04-25 · PMID 38704871 · DOI

Design and participants

Design
Cross-sectional study
Population
Adults with obstructive sleep apnea, with or without mild cognitive impairment, adults with MCI without OSA, and cognitively normal controls without OSA. None had dementia. A subgroup with moderate to severe OSA was followed during CPAP treatment.
Conditions
Obstructive sleep apnea, Mild cognitive impairment
Planned enrollment (registry)
Not reported
Enrolled
268
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): The authors concluded that mitochondrial dysfunction is implicated in cognitive impairment in OSA without dementia, mediates the link between intermittent hypoxia and cognition, and is partly reversible with CPAP. They propose mitochondrial proteins as markers of impairment.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: MOTS-c was only measured as an endogenous exosomal biomarker. It was never administered, so the study cannot inform effects of MOTS-c treatment.
    • inappropriate endpoint: Outcomes are biomarker levels and cognitive associations. No metabolic, safety or adverse event outcomes relate to MOTS-c administration.
    • confounding: This is an observational cross-sectional comparison of groups, and the abstract does not describe adjustment for confounders in the group comparisons.
    • small or imprecise: The CPAP follow-up included only 22 patients and had no control group.
    • abstract only: Only the PubMed abstract is available. Methods, funding and conflicts of interest are not reported in the record.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • arms: PMID 38704871, abstract (Results sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • author_conclusion: PMID 38704871, abstract (Conclusions, sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 38704871, abstract (Methods, sentences 1-4) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 38704871, abstract (Methods, sentences 2-4) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 38704871, abstract (Methods sentence 1; Results sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 38704871, abstract (Results sentence 1; Methods sentence 4) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).